Valley National Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Valley National Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$86K	Buy	194 +9	+5%	+$4.2K	0.01%	339
2025 Q4	$83K	Hold	185	–	–	0.01%	338
2025 Q3	$72K	Buy	185 +21	+13%	+$8.78K	0.01%	343
2025 Q2	$73K	Sell	164 -1	-0.6%	-$461	0.01%	342
2025 Q1	$79K	Buy	165 +43	+35%	+$20K	0.01%	321
2024 Q4	$49K	Hold	122	–	–	0.01%	359
2024 Q3	$56K	Sell	122 -39	-24%	-$18.7K	0.01%	346
2024 Q2	$75K	Buy	161 +10	+7%	+$4.34K	0.01%	340
2024 Q1	$63K	Sell	151 -23	-13%	-$9.72K	0.01%	379
2023 Q4	$70K	Buy	174 +43	+33%	+$15.9K	0.01%	356
2023 Q3	$46K	Buy	131 +5	+4%	+$1.75K	0.01%	397
2023 Q2	$45K	Hold	126	–	–	0.01%	403
2023 Q1	$42K	Hold	126	–	–	0.01%	411
2022 Q4	$36K	Hold	126	–	–	0.01%	421
2022 Q3	$38K	Buy	126 +4	+3%	+$1.15K	0.01%	407
2022 Q2	$36K	Hold	122	–	–	0.01%	394
2022 Q1	$32K	Hold	122	–	–	0.01%	446
2021 Q4	$27K	Buy	122 +10	+9%	+$1.95K	0.01%	462
2021 Q3	$20K	Sell	112 -14	-11%	-$2.73K	﹤0.01%	496
2021 Q2	$25K	Hold	126	–	–	﹤0.01%	458
2021 Q1	$27K	Hold	126	–	–	0.01%	411
2020 Q4	$30K	Hold	126	–	–	0.01%	382
2020 Q3	$34K	Hold	126	–	–	0.01%	324
2020 Q2	$37K	Buy	126 +14	+13%	+$3.8K	0.01%	317
2020 Q1	$27K	Hold	112	–	–	0.01%	340
2019 Q4	$25K	Hold	112	–	–	0.01%	398
2019 Q3	$19K	Hold	112	–	–	0.01%	436
2019 Q2	$21K	Sell	112 -6	-5%	-$1.05K	0.01%	395
2019 Q1	$22K	Hold	118	–	–	0.01%	379
2018 Q4	$20K	Hold	118	–	–	0.01%	365
2018 Q3	$23K	Hold	118	–	–	0.01%	337
2018 Q2	$20K	Sell	118 -33	-22%	-$5.12K	0.01%	346
2018 Q1	$25K	Hold	151	–	–	0.01%	312
2017 Q4	$23K	Hold	151	–	–	0.01%	311
2017 Q3	$23K	Buy	151 +6	+4%	+$903	0.01%	317
2017 Q2	$19K	Hold	145	–	–	0.01%	336
2017 Q1	$16K	Hold	145	–	–	0.01%	347
2016 Q4	$11K	Hold	145	–	–	0.01%	401
2016 Q3	$13K	Hold	145	–	–	0.01%	352
2016 Q2	$12K	Hold	145	–	–	0.01%	369
2016 Q1	$12K	Hold	145	–	–	0.01%	364
2015 Q4	$18K	Buy	145 +45	+45%	+$5.43K	0.01%	312
2015 Q3	$10K	Hold	100	–	–	0.01%	385
2015 Q2	$12K	Hold	100	–	–	0.01%	366
2015 Q1	$12K	Hold	100	–	–	0.01%	363
2014 Q4	$7K	Buy	+100	New	+$11.3K	0.01%	312

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Valley National Advisers's VRTX Position: Q1 2026 in Review

Valley National Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 4.9% in Q1 2026, buying an estimated $4.2K and bringing the position to 194 shares worth $86K. The position accounts for 0.01% of the portfolio, ranked #339.

Valley National Advisers first reported a position in VRTX in Q4 2014 and has held it in 46 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Valley National Advisers held 194 shares of Vertex Pharmaceuticals worth $86K as of Q1 2026.
Valley National Advisers bought 9 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.2K.
Vertex Pharmaceuticals made up 0.01% of Valley National Advisers's portfolio in Q1 2026, its #339 holding.
Valley National Advisers first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.